Cover Image

Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.

<h4>Background</h4>Treatment for post-kala-azar dermal leishmaniasis (PKDL) in Sudan is currently recommended only for patients with persistent or severe disease, mainly because of the limitations of current therapies, namely toxicity and long hospitalization. We assessed the safety and...

Full description

Saved in:

Bibliographic Details
Main Authors:	Brima Musa Younis (Author), Ahmed Mudawi Musa (Author), Séverine Monnerat (Author), Mohammed Abdelrahim Saeed (Author), Eltahir Awad Gasim Khalil (Author), Anas Elbashir Ahmed (Author), Mujahid Ahmed Ali (Author), Ali Noureldin (Author), Gina Muthoni Ouattara (Author), Godfrey M Nyakaya (Author), Samuel Teshome (Author), Truphosa Omollo (Author), Michael Ochieng (Author), Thaddaeus Egondi (Author), Mildred Mmbone (Author), Wan-Yu Chu (Author), Thomas P C Dorlo (Author), Eduard E Zijlstra (Author), Monique Wasunna (Author), Jorge Alvar (Author), Fabiana Alves (Author)
Format:	Book
Published:	Public Library of Science (PLoS), 2023-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study.
by: Ahmed M Musa, et al.
Published: (2010)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
by: Monique Wasunna, et al.
Published: (2016)

Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
by: Sarah Hendrickx, et al.
Published: (2017)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
by: Ridwanur Rahman, et al.
Published: (2017)

Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
by: Ahmed Musa, et al.
Published: (2012)

Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.
by: Asrat Hailu, et al.
Published: (2010)

Innovative approaches to clinical data management in resource limited settings using open-source technologies.
by: Raymond Omollo, et al.
Published: (2014)

Topical paromomycin for New World cutaneous leishmaniasis.
by: Néstor Sosa, et al.
Published: (2019)

Red blood cell distribution width and iron deficiency anemia among pregnant Sudanese women
by: Abdelrahman Esam G, et al.
Published: (2012)

Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.
by: Thomas P C Dorlo, et al.
Published: (2011)

Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
by: Wiwanitkit V
Published: (2012)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
by: Ermias Diro, et al.
Published: (2019)

Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model.
by: Luka Verrest, et al.
Published: (2024)

Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.
by: Eltahir A G Khalil, et al.
Published: (2014)

Prevalence of rotavirus infection among children with acute diarrhoea after rotavirus vaccine introduction in Kenya, a hospital cross-sectional study
by: Catherine Muendo, et al.
Published: (2018)

Two cases of endoscopically diagnosed amebic colitis treated with paromomycin monotherapy.
by: Kei Yamamoto, et al.
Published: (2020)

The health and well-being of older people in Nairobi's slums
by: Catherine Kyobutungi, et al.
Published: (2010)

Differences in the Cellular Immune Response during and after Treatment of Sudanese Patients with Post-kala-azar Dermal Leishmaniasis, and Possible Implications for Outcome
by: Ana Torres, et al.
Published: (2024)

Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition.
by: Dimitri Bulté, et al.
Published: (2021)

Successful treatment of multifocal cutaneous leishmaniasis with miltefosine
by: Bhushan Madke, et al.
Published: (2011)

Availability of miltefosine for the treatment of kala-azar in India
by: Shyam Sundar, et al.
Published: (2005)

A clinical algorithm for triaging patients with significant lymphadenopathy in primary health care settings in Sudan
by: Eltahir A.G. Khalil, et al.
Published: (2013)

High resistance of Pseudomonas aeruginosa to paromomycin, an agent used for selective bowel decontamination (SBD)
by: Daxboeck, Florian, et al.
Published: (2013)

Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh.
by: Kazi M Jamil, et al.
Published: (2015)

Complex cutaneous infection by Leishmania mexicana treated with miltefosine
by: Rachel L. Sadowsky, BA, et al.
Published: (2022)

Use of miltefosine in the treatment of cutaneous leishmaniasis in French Guiana
by: Charlene Oliveira, et al.
Published: (2024)

Chitosan nanoparticles improve the effectivity of miltefosine against Acanthamoeba.
by: Alireza Latifi, et al.
Published: (2024)

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major.
by: Kimbra G Turner, et al.
Published: (2015)

Crowdfunding approach for gene therapy: Experience from the UAE
by: Afnan Elbashir, et al.
Published: (2022)

Selective surgical ligation for post-traumatic arterio-biliary fistula
by: Walid Elhaj Abdelrahim, et al.
Published: (2018)

Co-occurrence of behavioral risk factors of common non-communicable diseases among urban slum dwellers in Nairobi, Kenya
by: Tilahun Nigatu Haregu, et al.
Published: (2015)

Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis.
by: Carolina Ferreira, et al.
Published: (2020)

Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran
by: Asilian A., et al.
Published: (2003)

Improvement of paromomycin production by Streptomyces rimosus subsp paromomycinus NRRL 2455 using gamma irradiation mutagenesis
by: Asmaa A. Ibrahim, et al.
Published: (2017)

Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol.
by: Sarah Hendrickx, et al.
Published: (2012)

Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.
by: Dae Hyun Kim, et al.
Published: (2009)

Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia.
by: Saskia van Henten, et al.
Published: (2021)

Monitoring Cutaneous Leishmaniasis Lesions in Mice Undergoing Topical Miltefosine Treatment
by: Laura Fernanda Neira, et al.
Published: (2023)

Genetic reconstruction of protozoan rRNA decoding sites provides a rationale for paromomycin activity against Leishmania and Trypanosoma.
by: Sven N Hobbie, et al.
Published: (2011)

Post-kala-azar dermal leishmaniasis developing in miltefosine-treated visceral leishmaniasis
by: Sankha Koley, et al.
Published: (2013)